(Reuters) -Teva Pharmaceutical will pay $225 million over five years to settle criminal price-fixing charges under a deal with the U.S. Department of Justice, the Israeli drugmaker said on Monday.
Teva, the world's largest generic drugmaker, will pay $22.5 million due each year from 2024 through 2027, and $135 million due in 2028.
The company has also agreed to donate $50 million worth of two generic products to humanitarian organizations and will divest one additional generic product to a third-party buyer.
The price-fixing charges related to conspiring with competitors to raise prices of generic drugs, and were brought against Teva in 2020.
(Reporting by Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
